J Immunother Cancer: The efficacy of nivolumab (nivolumab) combined with cabozantinib (cabozantinib) in patients with advanced endometrial cancer

Immunotherapy combined with antiangiogenic therapy for endometrial cancer is a promising therapeutic strategy
.

Recently, the journal J Immunother Cancer published the results of a phase II clinical study evaluating immune checkpoint inhibitors (nivolumab, nivolumab) in combination with anti-angiogenic drugs (cabozantinib, cabozantinib) in the treatment of patients without prior or Efficacy of immunotherapy in patients with endometrial cancer

Immunotherapy combined with antiangiogenic therapy for endometrial cancer is a promising therapeutic strategy

The researchers randomized patients with recurrent endometrial cancer in a 2:1 ratio to nivolumab in combination with cabozantinib (arm A) and nivolumab alone (arm B), with the primary endpoint being progression-free survival (PFS)
.

Patients with carcinosarcoma or prior immune checkpoint inhibitor therapy received combination therapy (group C)

The researchers randomized patients with recurrent endometrial cancer in a 2:1 ratio to nivolumab in combination with cabozantinib (arm A) and nivolumab alone (arm B), with the primary endpoint being progression-free survival (PFS)

Seventy-seven patients received treatment and were assessed for analysis: 36 in group A and 18 in group
B.

Median progression-free survival (PFS) was 5.

Seventy-seven patients received treatment and were assessed for analysis: 36 in group A and 18 in group

In the previous immunotherapy cohort (Group C; n=20), rechallenge with nivolumab in combination with cabozantinib resulted in an objective response in 5 patients (25%) and SD in 7 patients
.

Median SD duration was 5.

In the previous immunotherapy cohort (Group C; n=20), rechallenge with nivolumab in combination with cabozantinib resulted in an objective response in 5 patients (25%) and SD in 7 patients

Combination therapy is more prone to treatment-related toxicity than monotherapy
.

The most common treatment-related AEs in arm A were diarrhea, elevated liver enzymes, fatigue, and hypertension , with the exception of hypertension, which were usually grade 1/2

Combination therapy is more prone to treatment-related toxicity than monotherapy

Taken together, the study demonstrated that the addition of cabozantinib to nivolumab improved outcomes in patients with advanced endometrial cancer
.

Taken together, the study demonstrated that the addition of cabozantinib to nivolumab improved outcomes in patients with advanced endometrial cancer
.

Studies have shown that adding cabozantinib to nivolumab improves outcomes in patients with advanced endometrial cancer
.
Studies have shown that adding cabozantinib to nivolumab improves outcomes in patients with advanced endometrial cancer
.

Original source:

Original source:

Lheureux S, Matei DE, Konstantinopoulos PA, et al.
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer.
Journal for ImmunoTherapy of Cancer 2022;0:e004233.
doi:10.
1136/jitc- 2021-004233.

Lheureux S, Matei DE, Konstantinopoulos PA, et al.
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer.
Journal for ImmunoTherapy of Cancer 2022;0:e004233.
doi:10.
1136/jitc- 2021-004233.
Leave a message here